Bisphosphonates vs Exercise for the Prevention and Treatment of Osteoporosis

Journal for Nurse Practitioners

Volumn 8, Issue 3, 2012, Pages 217-224

  Hurley, Ben ^a   Armstrong, Terry Jessup ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b ManorCare of Carrollwood   (United States)

Author keywords

Bisphosphonates; Bone health; Exercise; Medications for osteoporosis; Physical activity and osteoporosis

Indexed keywords

EID: 84858224366     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2011.07.029     Document Type: Article

References (54)

1. U.S.Preventive Services Task Force Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement Accessed January 10, 2012. http://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.pdf.
2. National Osteoporosis Foundation Fast Facts. National Osteoporosis Foundation Accessed January 10, 2012. http://www.nof.org/node/40.
3. National Osteoporosis Foundation Clinician's guide to prevention and treatment of osteoporosis 2010, The Foundation, Washington, DC.
4. Civitelli R, Armamento-Villareal R, Napoli N Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009, 20(6):843-851.
5. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005, 20(10):1813-1819.
6. Looker AC, Dawson-Hughes B, Tosteson AN, Johansson H, Kanis JA, Melton LJ Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance. Osteoporos Int 2011, 22(2):541-549.
7. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 2009, 24(4):675-680.
8. Silverman SL, Maricic M Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 2007, 37(1):1-12.
9. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 2010, 182(17):1864-1873.
10. Bilezikian JP Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 122(2 Suppl):S14-S21.
11. Pazianas M, Cooper C, Ebetino FH, Russell RG Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010, 6:325-343.
12. Bonnick SL, Shulman L Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 2006, 119(4 Suppl 1):S25-S31.
13. Michaelsson K, Olofsson H, Jensevik K, et al. Leisure physical activity and the risk of fracture in men. PLoS Med 2007, 4(6):e199.
14. Feskanich D, Willett W, Colditz G Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002, 288(18):2300-2306.
15. Boonyaratavej N, Suriyawongpaisal P, Takkinsatien A, Wanvarie S, Rajatanavin R, Apiyasawat P Physical activity and risk factors for hip fractures in Thai women. Osteoporos Int 2001, 12(3):244-248.
16. Moayyeri A The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol 2008, 18(11):827-835.
17. Guadalupe-Grau A, Fuentes T, Guerra B, Calbet JA Exercise and bone mass in adults. Sports Med 2009, 39(6):439-468.
18. Vondracek SF, Linnebur SA Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging 2009, 4:121-136.
19. Li WC, Chen YC, Yang RS, Tsauo JY Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. Clin Rehabil 2009, 23(10):888-896.
20. van Brussel MS, Bultink IE, Lems WF Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 2009, 10(6):997-1005.
21. Braith RW, Magyari PM, Fulton MN, Aranda J, Walker T, Hill JA Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J Heart Lung Transplant 2003, 22(10):1082-1090.
22. Cefalu CA Is bone mineral density predictive of fracture risk reduction?. Curr Med Res Opin 2004, 20(3):341-349.
23. Lindsay RCF Osteoporosis. Harrison's Principles of Internal Medicine 2005, 2268-2278. McGraw Hill, New York. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo (Eds.).
24. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006, 65(5):654-661.
25. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282(14):1344-1352.
26. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357(18):1799-1809.
27. Cussler EC, Lohman TG, Going SB, et al. Weight lifted in strength training predicts bone change in postmenopausal women. Med Sci Sports Exerc 2003, 35(1):10-17.
28. Beck TJ, Kohlmeier LA, Petit MA, et al. Confounders in the Association between Exercise and Femur Bone in Postmenopausal Women. Med Sci Sports Exerc 2010, 43(1):80-89.
29. Turner CH, Robling AG Designing exercise regimens to increase bone strength. Exerc Sport Sci Rev 2003, 31(1):45-50.
30. Lu TW, Taylor SJ, O'Connor JJ, Walker PS Influence of muscle activity on the forces in the femur: an in vivo study. J Biomech 1997, 30(11-12):1101-1106.
31. Umemura Y, Ishiko T, Yamauchi T, Kurono M, Mashiko S Five jumps per day increase bone mass and breaking force in rats. J Bone Miner Res 1997, 12(9):1480-1485.
32. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009, 7(3):101-107.
33. Courtney A, Wachtel E, Myers E, Hayes W Effects of loading rate on strength of the proximal femur. Calcified Tissue Int 1994, 55:53-58.
34. Widrick JJ, Fuchs R, Maddalozzo GF, Marley K, Snow C Relative effects of exercise training and alendronate treatment on skeletal muscle function of ovariectomized rats. Menopause 2007, 14(3 Pt 1):528-534.
35. Delmas PD, Seeman E Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004, 34(4):599-604.
36. Bouxsein ML, Seeman E Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 2009, 23(6):741-753.
37. Small RE Uses and limitations of bone mineral density measurements in the management of osteoporosis. Med Gen Med 2005, 7(2):3-8.
38. Garnero P Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008, 12(3):157-170.
39. Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 2006, 26(1):104-114.
40. Bouxsein ML, Karasik D Bone geometry and skeletal fragility. Curr Osteoporos Rep 2006, 4(2):49-56.
41. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
42. Di Munno O, Sedle AD Efficacy of ibandronate: a long term confirmation. Clin Cases Miner Bone Metab 2011, 7(1):23-26.
43. Mashiba T, Turner CH, Hirano T, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 2001, 29(3):271-278.
44. Allen MR, Iwata K, Phipps R, Burr DB Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39(4):872-879.
45. Schilcher J, Michaelsson K, Aspenberg P Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364(18):1728-1737.
46. Seeman E, Delmas PD Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354(21):2250-2261.
47. Saxon LK, Lanyon LE Assessment of the in vivo adaptive response to mechanical loading. Methods Mol Biol 2008, 455:307-322.
48. Turner CH, Robling AG Mechanisms by which exercise improves bone strength. J Bone Miner Metab 2005, 23(Suppl):16-22.
49. Robling AG, Hinant FM, Burr DB, Turner CH Improved bone structure and strength after long-term mechanical loading is greatest if loading is separated into short bouts. J Bone Miner Res 2002, 17(8):1545-1554.
50. Puustjarvi K, Nieminen J, Rasanen T, et al. Do more highly organized collagen fibrils increase bone mechanical strength in loss of mineral density after one-year running training?. J Bone Miner Res 1999, 14(3):321-329.
51. Warden SJ, Fuchs RK, Castillo AB, Nelson IR, Turner CH Exercise when young provides lifelong benefits to bone structure and strength. J Bone Miner Res 2007, 22(2):251-259.
52. Nikander R, Sievanen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med 2010, 8:47.
53. American College of Sports Medicine ACSM's Guidelines for Exercise Testing and Prescription 2010, Wolters Kluwer/Lippincott Williams & Wilkins. 8th ed.
54. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. Med Sci Sports Exerc 2009, 41(7):1510-1530.